News EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 Staff September 11, 2023 Iframe sync Post navigation Previous: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerNext: Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer More Stories News TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS Staff December 6, 2025 Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025 Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025
